During the last session, Dexcom Inc (NASDAQ:DXCM)’s traded shares were 2.43 million, with the beta value of the company hitting 1.21. At the end of the trading day, the stock’s price was $138.93, reflecting an intraday gain of 4.19% or $5.59. The 52-week high for the DXCM share is $142.00, that puts it down -2.21 from that peak though still a striking 46.2% gain since the share price plummeted to a 52-week low of $74.75. The company’s market capitalization is $53.56B, and the average intraday trading volume over the past 10 days was 2.42 million shares, and the average trade volume was 3.11 million shares over the past three months.
Dexcom Inc (NASDAQ:DXCM) trade information
Dexcom Inc (DXCM) registered a 4.19% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.19% in intraday trading to $138.93, hitting a weekly high. The stock’s 5-day price performance is 0.17%, and it has moved by 3.90% in 30 days. Based on these gigs, the overall price performance for the year is 20.14%. The short interest in Dexcom Inc (NASDAQ:DXCM) is 15.87 million shares and it means that shorts have 4.17 day(s) to cover.
Dexcom Inc (DXCM) estimates and forecasts
Statistics show that Dexcom Inc has outperformed its competitors in share price, compared to the industry in which it operates. Dexcom Inc (DXCM) shares have gone up 58.42% during the last six months, with a year-to-date growth rate more than the industry average at 15.79% against 13.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 58.80% this quarter and then jump 14.70% in the quarter after that. In the rating firms’ projections, revenue will increase 19.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $909.92 million as predicted by 20 analyst(s). Meanwhile, a consensus of 20 analyst(s) estimates revenue growth to $1.05 billion by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $720.74 million and $841.62 million respectively. In this case, analysts expect current quarter sales to grow by 26.20% and then jump by 24.30% in the coming quarter.
While earnings are projected to return 15.38% in 2024, the next five years will return 33.40% per annum.
DXCM Dividends
Dexcom Inc is due to release its next quarterly earnings on April 25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Dexcom Inc (NASDAQ:DXCM)’s Major holders
Dexcom Inc insiders own 0.42% of total outstanding shares while institutional holders control 102.95%, with the float percentage being 103.39%. Vanguard Group Inc is the largest shareholder of the company, while 1,429 institutions own stock in it. As of Jun 29, 2023, the company held over 44.28 million shares (or 11.42% of all shares), a total value of $5.69 billion in shares.
The next largest institutional holding, with 33.25 million shares, is of Blackrock Inc.’s that is approximately 8.57% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $4.27 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Dexcom Inc (DXCM) shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 12.1 million shares. This amounts to just over 3.12 percent of the company’s overall shares, with a $1.56 billion market value. The same data shows that the other fund manager holds slightly less at 9.23 million, or about 2.38% of the stock, which is worth about $1.19 billion.
